BSX Stock Analysis: Boston Scientific | NYSE
Medical Devices | NYSE, USA | Market Cap: 65.099m USD | 12M Return: -55.3% | US1011371077 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 925M
EPS Trend: 99.3%
Qual. Beats: 1
Rev. Trend: 99.6%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Boston Scientific Corporation (NYSE: BSX) is a U.S.-based medical device manufacturer that develops, produces, and markets products for interventional medical specialties across two operating segments: MedSurg and Cardiovascular. Its portfolio spans gastrointestinal and urological devices, neurological systems for chronic pain and movement disorders, and a broad set of cardiology offerings including the WATCHMAN FLX left atrial appendage closure device, implantable cardiac monitors, defibrillators, and pacemakers. The company also serves peripheral vascular and oncology markets, distributing its products worldwide. Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific has been listed on the NYSE since its 1992 IPO and is classified within the Health Care Equipment sub-industry.
The medical device sector is characterized by long product development cycles, regulatory oversight from agencies such as the U.S. Food and Drug Administration, and competition from other large diversified device makers including Medtronic, Abbott, and Johnson & Johnson. Boston Scientifics business model relies on a mix of recurring revenue from consumables and implantables, ongoing R&D investment to refresh its product pipeline, and global sales channels that allow it to serve hospitals, ambulatory surgery centers, and specialty physician practices across more than 100 countries.
- WATCHMAN FLX adoption drives structural heart segment revenue growth
- Axonics acquisition expands neuromodulation share against Medtronic competition
- China volume-based procurement pressures urology and endoscopy margins
| Net Income: 3.67b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.05 > 1.0 |
| NWC/Revenue: 7.35% < 20% (prev 10.44%; Δ -3.09% < -1%) |
| CFO/TA 0.10 > 3% & CFO 4.53b > Net Income 3.67b |
| Net Debt (12.2b) to EBITDA (5.51b): 2.21 < 3 |
| Current Ratio: 1.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.48b) vs 12m ago -0.56% < -2% |
| Gross Margin: 71.16% > 18% (prev 63.23%; Δ 7.94% > 0.5%) |
| Asset Turnover: 48.39% > 50% (prev 44.50%; Δ 3.89% > 0%) |
| Interest Coverage Ratio: 11.64 > 6 (EBIT TTM 4.22b / Interest Expense TTM 363.0m) |
| A: 0.03 (Total Current Assets 7.97b - Total Current Liabilities 6.43b) / Total Assets 45.2b |
| B: 0.17 (Retained Earnings 7.82b / Total Assets 45.2b) |
| C: 0.10 (EBIT TTM 4.22b / Avg Total Assets 43.4b) |
| D: 1.24 (Book Value of Equity 24.9b / Total Liabilities 20.0b) |
| Altman-Z'' = 2.75 = A |
| DSRI: 0.95 (Receivables 3.05b/2.81b, Revenue 21.0b/18.5b) |
| GMI: 0.89 (GM 63.23% / 71.16%) |
| AQI: 1.00 (AQ_t 0.73 / AQ_t-1 0.73) |
| SGI: 1.14 (Revenue 21.0b / 18.5b) |
| TATA: -0.02 (NI 3.67b - CFO 4.53b) / TA 45.2b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of September 28, 2026, the stock is trading at USD 43.92 with a total of 14,993,609 shares traded. Over the past week, the price has changed by +1.34%, over one month by -11.91%, over three months by -0.63% and over the past year by -55.25%.
Current recommended Stop Loss: 41.20 (which is 6.2% or 1.8 ATR below the current price).
Boston Scientific has received a consensus analysts rating of 4.59. Therefore, it is recommended to buy BSX.
- StrongBuy: 23
- Buy: 8
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 61.1 | 39% |
P/E Trailing = 17.685
P/E Forward = 12.9534
P/S = 3.1006
P/B = 2.5415
P/EG = 0.6125
Revenue TTM = 21.0b USD
EBIT TTM = 4.22b USD
EBITDA TTM = 5.51b USD
Long Term Debt = 10.8b USD (from longTermDebt, last quarter)
Short Term Debt = 1.71b USD (from shortTermDebt, last quarter)
Debt = 12.7b USD (from shortLongTermDebtTotal, last quarter) + Leases 124.0m
Net Debt = 12.2b USD (calculated: Debt 12.7b - CCE 539.0m)
Enterprise Value = 77.3b USD (65.1b + Debt 12.7b - CCE 539.0m)
Interest Coverage Ratio = 11.64 (Ebit TTM 4.22b / Interest Expense TTM 363.0m)
EV/FCF = 21.33x (Enterprise Value 77.3b / FCF TTM 3.62b)
FCF Yield = 4.69% (FCF TTM 3.62b / Enterprise Value 77.3b)
FCF Margin = 17.27% (FCF TTM 3.62b / Revenue TTM 21.0b)
Net Margin = 17.47% (Net Income TTM 3.67b / Revenue TTM 21.0b)
Gross Margin = 71.16% ((Revenue TTM 21.0b - Cost of Revenue TTM 6.05b) / Revenue TTM)
Gross Margin QoQ = 70.71% (prev 69.44%)
Tobins Q-Ratio = 1.71 (Enterprise Value 77.3b / Total Assets 45.2b)
Interest Expense / Debt = 2.85% (Interest Expense 363.0m / Debt 12.7b)
Taxrate = 5.00% (193.0m / 3.86b)
NOPAT = 4.01b (EBIT 4.22b * (1 - 5.00%))
Current Ratio = 1.24 (Total Current Assets 7.97b / Total Current Liabilities 6.43b)
Debt / Equity = 0.51 (Debt 12.7b / totalStockholderEquity, last quarter 24.9b)
Debt / EBITDA = 2.21 (Net Debt 12.2b / EBITDA 5.51b)
Debt / FCF = 3.37 (Net Debt 12.2b / FCF TTM 3.62b)
Total Stockholder Equity = 24.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.45% (Net Income 3.67b / Total Assets 45.2b)
RoE = 14.90% (Net Income TTM 3.67b / Total Stockholder Equity 24.6b)
RoCE = 11.93% (EBIT 4.22b / Capital Employed (Equity 24.6b + L.T.Debt 10.8b))
RoIC = 10.04% (NOPAT 4.01b / Invested Capital 40.0b)
WACC = 6.83% (E(65.1b)/V(77.8b) * Re(7.64%) + D(12.7b)/V(77.8b) * Rd(2.85%) * (1-Tc(0.05)))
Discount Rate = 7.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 57.20 | Cagr: 0.10%
[DCF] Terminal Value 76.60% ; FCFF base≈3.50b ; Y1≈3.79b ; Y5≈4.67b
[DCF] Fair Price = 40.92 (EV 71.5b - Net Debt 12.2b = Equity 59.3b / Shares 1.45b; r=8.35% [WACC [floored]]; 5y FCF grow 9.48% → 2.50% )
EPS Correlation: 99.27 | EPS CAGR: 21.12% | SUE: 1.41 | # QB: 1
Revenue Correlation: 99.63 | Revenue CAGR: 18.03% | SUE: 1.25 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.77 | Chg30d=-3.99% | Revisions=-88% | Analysts=22
EPS current Year (2026-12-31): EPS=3.28 | Chg30d=-0.82% | Revisions=-89% | GrowthEPS=+7.1% | GrowthRev=+6.1%
EPS next Year (2027-12-31): EPS=3.42 | Chg30d=-0.40% | Revisions=-50% | GrowthEPS=+4.4% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: -94% (up=0, down=49)